Hematopoietic stem cell transplantation (HSCT) is the process that entails the intravenous infusion of hematopoietic stem cells with a view to reinstate blood cell production in patients whose immune system or bone marrow is defective or damaged. During the last half century, this approach has been employed with higher frequency to address several malignant and non-malignant ailments.

Cells for HSCT are likely to be acquired from the patient herself or himself (autologous transplant) or may be from another person, such as a sibling or unlinked donor (allogeneic transplant) or an siamese twin (syngeneic transplant). The cell sources comprise bone marrow; umbilical cord blood, peripheral blood, or, scarcely ever, fetal liver.

Hematopoietic Stem Cell Transplantation (HSCT) Market Dynamics

One of the most significant factors that is essentially affecting the demand of hematopoietic stem cell transplantation is the growing prevalence of leukemia and lymphoma among the population all across the world. To support that, as per the reports of Leukemia & Lymphoma Society, about every 3 minutes, one person in the United States is diagnosed with leukemia, myeloma or lymphoma.

Moreover, an approximate 1,519,907 people in the United States (US) are coexisting with leukemia, myeloma, lymphoma, myeloproliferative neoplasms (MPNs) or myelodysplastic syndromes (MDS). Attributing to such factors, the global hematopoietic stem cell transplantation (HSCT) market is projected to grow swiftly in the following years.

On top of that, it is believed that outcomes for hematopoietic stem cell transplants (HSCT) have been, for the most part, positive for autoimmune diseases, for instance Multiple Sclerosis, in which the immune system damages a patient’s body. Said factors are further expected to drive the demand of hematopoietic stem cell transplantation (HSCT) across the global markets, ultimately projected to offer lucrative opportunities to the market growth over the forecast period.

Hematopoietic Stem Cell Transplantation (HSCT) Market Segmentation

The global Hematopoietic Stem Cell Transplantation (HSCT) market is segmented on the basis of transplant type, indication, application and region.

By Transplant Type

Allogeneic

Autologous

By Indication

Acute Myeloid Leukemia (AML)

Acute Lymphoblastic Leukemia (ALL)

Hodgkin lymphoma (HL)

Non-Hodgkin Lymphoma (NHL)

Multiple Myeloma (MM)

Other Non-Malignant Disorders

By Application

Bone Marrow Transplant (BMT)

Peripheral Blood Stem Cells Transplant (PBSCT)

Cord Blood Transplant (CBT)

By Region

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

Hematopoietic Stem Cell Transplantation (HSCT) Market Key Players

The key participating players of the global Hematopoietic Stem Cell Transplantation (HSCT) market include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd., among others.

Reports & Insights Overview on Hematopoietic Stem Cell Transplantation (HSCT) Market Report

The non-identical approach of Reports & Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the Hematopoietic Stem Cell Transplantation (HSCT) market by Reports & Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance

Reimbursement

Concerns for use of Hematopoietic Stem Cell Transplantation (HSCT)

Advantages of Hematopoietic Stem Cell Transplantation (HSCT)

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to make informed decisions.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment where one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the global market.